Argenx Reports 18 Consecutive Quarters of Sales Growth and Expanding Profitability
Biotech company Argenx has achieved an impressive streak of 18 consecutive quarters of revenue growth, with sales rising by 60% year over year in Q2 2026. The company's Vyvgart therapies are driving this momentum as they gain traction for treating severe autoimmune diseases like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Argenx also reported a significant increase in earnings, with profits nearly doubling compared to the prior year period. The company's operating margins continue to expand, positioning it as a strong player in its market segments. CFO Karl Gubitz noted that competitors are lagging behind Vyvgart and highlighted substantial untapped potential for growth. Looking ahead, Argenx is preparing multiple key announcements from late-stage clinical trials across several autoimmune conditions. Analysts remain optimistic about the stock's future performance despite a high valuation relative to forward earnings.
Topics: biotech profitability revenue_growth